FDA approves Corstasis’ bumetanide nasal spray to treat edema in heart, liver, and kidney disease

Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl

Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use

Imfinzi perioperative regimen improved survival across muscle-invasive bladder cancer patients

Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone

Edwards’ SAPIEN 3 Ultra RESILIA Valve demonstrates positive outcome

Dupixent Phase 3 data showed significant histological remission of eosinophilic esophagitis

68% of children on a higher dose of Dupixent achieved histological disease remission at week 16

USFDA approves first treatment option for generalized pustular psoriasis flares in adults

Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares

Urologists explore the role of robotics, equity, exercise and medicine on bladder cancer

Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)

USFDA approves CITI Biopharma’s Vonjo

Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients

Prof. Jason Kovacic bags Agilent Thought Leader award

Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease